ResMed Inc. 10-Q Filing Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation that designs, manufactures, and markets devices for the evaluation and treatment of sleep disordered breathing, primarily obstructive sleep apnea. The reporting period covers the three months ended September 30, 2002. The company operates manufacturing facilities in Australia, Germany, and the United States, with major distribution sites globally.
Key Financial Metrics
| Metric | Q1 2003 (Ended Sep 30, 2002) | Q1 2002 (Ended Sep 30, 2001) |
|---|---|---|
| Net Revenue | $58.6 million | $46.1 million |
| Gross Profit | $37.7 million | $30.8 million |
| Gross Margin | 64.3% | 66.8% |
| Operating Income | $15.5 million | $13.2 million |
| Net Income | $9.6 million | $8.5 million |
| Diluted EPS | $0.28 | $0.25 |
| Cash from Operations | $8.1 million | $11.2 million |
| Cash & Equivalents (End of Period) | $73.6 million | $60.4 million |
| Convertible Notes Outstanding | $118.3 million | $123.3 million (Prior Qtr) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 27% year-over-year, driven by a 22% increase in flow generator unit sales and a 33% increase in mask system and accessory sales. International revenue grew 23%, while North and Latin American revenue grew 31%.
- Margin Compression: Gross margin decreased from 67% to 64%. Management attributes this to lower margins from recently acquired subsidiaries (MAP and Servo Magnetics Inc.) and the appreciation of the Australian dollar against the U.S. dollar, which increased manufacturing costs.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 25% due to personnel expansion. Research and development (R&D) expenses increased 31% due to currency effects and increased spending on new product development (Mirage Vista mask, S7 flow generator).
- Debt Reduction: The company repurchased $5.0 million face value of its convertible subordinated notes during the quarter, recognizing a gain of $0.2 million.
Outlook, Risks, and Unusual Items
- Acquisitions: The quarter included the acquisition of John Stark and Associates ($300,000) and the full quarter impact of Servo Magnetics Inc. (acquired May 2002).
- Capital Expenditures: Capital spending was $4.8 million, primarily for a new manufacturing facility in Sydney, Australia, and a disaster recovery system. The company expects to complete the first building on the new site in fiscal year 2004.
- Litigation: ResMed is engaged in significant patent litigation against Respironics, Inc. and Fisher & Paykel Healthcare regarding mask product infringement. The company intends to appeal summary judgment rulings in the Respironics case.
- Foreign Exchange Risk: The company faces exposure to fluctuations in the Australian dollar and Euro. While hedging programs are in place, currency movements impacted gross margins and resulted in foreign currency losses on derivatives.
- Stock Repurchases: The company repurchased 70,300 shares of common stock for $1.9 million during the quarter under a board-authorized program.
Investor Verification Checklist
- Acquisition Integration: Verify the integration progress and margin performance of Servo Magnetics Inc. and Labhardt AG, which are currently diluting overall gross margins.
- Currency Hedging Effectiveness: Monitor the impact of the Australian dollar's strength on future cost of sales and the effectiveness of the foreign currency option hedging program.
- Litigation Outcomes: Track the status of patent lawsuits against Respironics and Fisher & Paykel, as adverse rulings could impact market share or result in licensing fees.
- Capital Project Timeline: Confirm the construction schedule and cost estimates for the new Sydney manufacturing facility to ensure it aligns with projected capacity needs.
- Debt Management: Review the company's strategy for managing the remaining $118.3 million in convertible notes, including potential future repurchases or conversions.